Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
PvHMB-CCE001
- Development stage
- Preclinical
- Lead developer
- National Institute of Allergy and Infectious Diseases
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intravenous
01
Overview
PvHMB-CCE001 is a biological challenge agent used in controlled human malaria infection (CHMI) studies. It consists of erythrocytes (red blood cells), both infected and uninfected, stabilized in glycerolyte, and is derived from Plasmodium vivax. The primary use of PvHMB-CCE001 is to induce blood-stage P. vivax malaria in healthy volunteers for the purpose of evaluating vaccines or antimalarial drugs under controlled conditions[1][2]. This agent does not function as a therapeutic drug but rather as a research tool to facilitate the study of malaria pathogenesis and intervention efficacy.
- Other names
- PvHMB-CCE001PvHMB-CCE-001PvHMB-CCE 001
Beyond the preview
Go deeper on PvHMB-CCE001.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on PvHMB-CCE001.